NOVARTIS PHARMACEUTICALS UK LTD (WT) - WT2024-11, WT2024-12, WT2024-13 - RIBOCICLIB [KISQALI] (AS SUCCINATE) 200 mg Tablets, SECUKINUMAB (COSENTYX) 150 mg in 1mL & 300 mg in 2mLInjections
What the buyer wrote
Supply of RIBOCICLIB [KISQALI] (AS SUCCINATE) 200 mg Tablets to meet clinical need in the Western Trust until 15/08/2027. Supply of SECUKINUMAB (COSENTYX) 150 mg in 1mL & 300mg in 2mL Injections to meet clinical need in the Western Trust until 03/08/2025.
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- NOVARTIS PHARMACEUTICALS UK LTD (WT) - WT2024-11, WT2024-12, WT2024-13 - RIBOCICLIB [KISQALI] (AS SUCCINATE) 200 mg Tablets, SECUKINUMAB (COSENTYX) 150 mg in 1mL & 300 mg in 2mLInjections
- How they are buying
- Given to one supplier, no competitionNobody else was asked, and the buyer has to be able to justify that.
- Type
- goods
- Where
- in Northern Ireland
- Kind of work
- Pharmacy and medicines
Who the buyer named
Martin Robinson was the named contact on this notice.